Related Experiment Videos
Basic fibroblast growth factor enhanced LAK cell cytotoxicities against human bladder neoplasm cells
1Institute of Urology, 2nd Affiliated Hospital of Lanzhou Medical College, China.
Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica
|August 19, 1999
Summary
Basic fibroblast growth factor (bFGF) enhances the cancer-killing ability of lymphokine-activated killer (LAK) cells in bladder cancer patients, despite inhibiting peripheral blood monocyte proliferation.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Bladder cancer poses a significant health challenge.
- Lymphokine-activated killer (LAK) cells are crucial for cellular immunotherapy.
- Investigating novel growth factors to enhance LAK cell efficacy is vital.
Purpose of the Study:
- To evaluate the impact of basic fibroblast growth factor (bFGF) on LAK cell proliferation.
- To assess the effect of bFGF on LAK cell-mediated cytotoxicity against bladder tumor cells.
Main Methods:
- LAK cell proliferation was measured using cell counts with varying bFGF and interleukin-2 (IL-2) concentrations.
- Cytotoxicity was determined using MTT assays against bladder cancer cell lines (EJ) and patient-derived bladder tumor cells (BTC).
Main Results:
- bFGF at 5 µg/L inhibited peripheral blood monocyte (PBMC) proliferation.
- bFGF did not alter IL-2-induced LAK cell stimulation or cell numbers.
- bFGF significantly enhanced LAK cell cytotoxicity against EJ cells and BTC.
Conclusions:
- bFGF demonstrates a dual effect: inhibiting PBMC proliferation while boosting LAK cell anti-tumor activity.
- bFGF holds potential as an adjunct therapy to improve LAK cell-based treatments for bladder cancer.